Raloxifene decreases cell viability and migratory potential in prostate cancer cells (LNCaP) with GPR30/GPER1 involvement

ConclusionsRaloxifene was able to modulate GPER1 in LNCaP prostate tumour cells, decreasing cell viability and their migratory potential.

Source: Journal of Pharmacy and Pharmacology - March 27, 2019 Category: Drugs & Pharmacology Authors: Giovanna Cassone Salata, Cristiane Figueiredo Pinho, Andr é T. A. G. Freitas, Ariana Musa Aquino, Luis Antonio Justulin, Leonardo Oliveira Mendes, Bianca F. Gonçalves, Flávia Karina Delella, Wellerson Rodrigo Scarano Tags: Research Paper Source Type: research